ARTICLE | Company News
Genzyme, Ablynx partner in MS
May 19, 2015 12:29 AM UTC
Ablynx N.V. (Euronext:ABLX) and the Genzyme Corp. unit of Sanofi (Euronext:SAN; NYSE:SNY) partnered to develop Nanobodies against an undisclosed multiple sclerosis target. Ablynx's Nanobodies are therapeutic proteins based on single-domain antibody fragments.
Neither company would discuss the target, but Ablynx said the program would align with Genzyme's early stage research involving neuroprotection and CNS repair, intended to slow disease progression. ...